Please login to the form below

Using service design to improve patients’ quality of life

Customer Experience Consultant Eimear Power talks through the process of developing Orello, a service for metastatic prostate cancer patients and their loved ones, in collaboration with Janssen.
This year, Janssen launched Orello, a service for metastatic prostate cancer patients and their loved ones. Blue Latitude Health supported Janssen in their journey to uncover real patient needs to develop the service with the aim of improving the quality of life for men living with prostate cancer.

From initial research through to final execution, developing a patient service like Orello is a truly multidisciplinary process. Each of our internal capabilities was involved in this project, as were a variety of client stakeholders – a wide breadth of expertise and knowledge contributed to the development of the service.

Customer Experience Consultant Eimear Power talks through the process of developing Orello in collaboration with Janssen.

The importance of empathy in service design: uncovering patients’ real needs

Empathy is at the heart of service design, particularly when designing a service for patients. Qualitative research was central to this project. As much as possible, we wanted to look at these patients through an ethnographic lens. We wanted to understand how these men thought about their disease, and how it affected their everyday lives. What were their biggest concerns and worries? What was it like to be a partner to someone with prostate cancer? What were the partners’ needs, and how did those relate to patient needs?

One thing that really made this project stand out was the emphasis on the carer and their needs. The carer was not viewed as secondary to the patient, they were considered equally in the design process.

Many markets experience cost constraints within the healthcare system that mean that emotional related support is reluctantly deprioritised, often with the carer not in the frame at all. Therefore, it is invaluable when pharma can bridge this gap in any small way. The service aimed to do this, and the first step was to understand the support needs.

As with many clients, Janssen already had existing research and we were able to bring it all together to get as rich a picture as possible. It’s not always about starting from scratch. There were also company initiatives already in place, and we ensured that we understood their objectives and challenges; our goal was to complement or integrate with them where possible.

Our team had the privilege of spending time with patients and their families in their homes, which was invaluable in enabling the team to build empathy and a deep understanding of patient and carer needs. The insight gained during this research phase was the cornerstone of generating concepts for the service.

From the research, a picture began to come into focus. Some of the key insights the team drew on when developing concepts:
  • Carers struggled to define the support they may benefit from, but they clearly needed support.
  • Many men didn’t know how or didn’t want to talk about how they felt, and this sometimes led to relationship issues.
  • The emotional impact of adapting to and dealing with the side effects of prostate cancer treatment can lead to feelings of emasculation due to ‘Feminisation’ brought on by treatment, sparking deeper issues for the couple.
  • Practical issues, such as sorting out finances, can loom over couples and be the source of anxiety and worry.
  • Life goes on after a diagnosis of prostate cancer, and where possible, the goal is to live life as normally as possible.

CX artefacts help facilitate commercial conversations

The research we conducted with patients was used to develop patient journeys and personas, this not only allowed the team to understand what the patient was feeling, thinking, and doing at any one phase of their prostate cancer but it was also incredibly useful for facilitating conversations around the commercial objectives of the service.

Unfortunately, you cannot be everything to everyone, so the team needed to identify which patients we could best support, and at what point in the journey we felt it would be of most value. It was decided that the objective of the service would be to support patients and their families who are living with mCRPC by improving their quality of life.




Download the full article from Blue Latitude Health 

30th March 2017

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and launch of precision medicines.
Blue Latitude Health
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in development. So how can pharma ensure its product stands out from the crowd?
Blue Latitude Health
How ready are you for launch?
Pharmaceutical launches are becoming more complex and competitive. Our launch excellence diagnostic tool helps you to map how ready you are for launch, while facilitating success in this challenging environment.
Blue Latitude Health
Does your pre-launch strategy really drive behaviour change?
One of the most interesting parts of a pharmaceutical launch is delving into the minds of stakeholders to understand why they behave in the way that they do. Blue Latitude Health Insight Consultant, Dorrotya Okros, examines how we use these insights to understand customers decision making behaviour, in order to make smarter business decisions.
Blue Latitude Health
Digitalising healthcare: what can the NHS learn from other industries?
Expensive digital solutions are often disregarded because they do not work well for the end user. Account Manager Fiona Grace explores this challenge and reveals the stories of innovation we can all learn from.
Blue Latitude Health
UK vs US: what makes a successful immunisation programme?
Emily Macdonald calls on her experience as a public health nurse specialising in the prevention of infectious disease in both the US and UK, to explore the differences between immunisation programmes in the two countries. She explores the challenges, opportunities for improvement, and asks why vaccination rates are falling.
Blue Latitude Health